Top

Published in:

01-02-2015 | Review Article

Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia

Authors: Sol Cortés de Miguel, Miguel Ángel Calleja-Hernández, Salomón Menjón-Beltrán, Inmaculada Vallejo-Rodríguez

Published in: Supportive Care in Cancer | Issue 2/2015

Abstract

Myelosuppression secondary to chemotherapy remains a serious adverse effect of cancer therapy that causes high morbidity and mortality. Several current European and American guidelines recommend consideration of primary prophylaxis with colony-stimulating factors (CSFs) when the risk of febrile neutropenia is higher than 20 %. The main factors associated with a high risk of febrile neutropenia include the chemotherapy regimen, tumor type, and patient-related factors such as old age and/or comorbidities. The purpose of this paper is to summarize the most relevant clinical trials and updated recommendations of the main guidelines on the role of granulocyte colony-stimulating factors (G-CSFs) in febrile neutropenia, examining whether the combination of G-CSF with chemotherapy improves overall survival. Future directions for G-CSF use are also discussed.

Fortner BV, Houts AC, Schwartzberg LS (2006) A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol 4:472–478PubMed

Padilla G, Ropka ME (2005) Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 28:167–171PubMedCrossRef

Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23–35. doi:10.3816/SCT.2003.n.002 PubMedCrossRef

Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984. doi:10.1200/JCO.2004.00.7955 PubMedCrossRef

Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217. doi:10.1136/bmj.38314.622095.8F PubMedCentralPubMedCrossRef

Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524–4531. doi:10.1200/JCO.2003.05.002 PubMedCrossRef

Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901–906. doi:10.1056/NEJM199504063321401 PubMedCrossRef

Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMedCrossRef

Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332. doi:10.1056/NEJM199305063281808 PubMedCrossRef

10.

Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (2006) US National Cancer Institute. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed Dec 2013

11.

Common Terminology Criteria for Adverse Events (CTCAE).v4.0 (2010) Department of Health and Human Services, National Institutes of Health. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed Dec 2013

12.

Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. doi:10.1093/cid/cir073 PubMedCrossRef

13.

Hughes WT, Armstrong D, Bodey GP et al (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Inf Dis Soc Am Clin Infect Dis 25:551–573CrossRef

14.

Meza L, Baselga J, Holmes FA, Liang BBJ (2002) Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 21:255b

15.

Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109–118PubMed

16.

Aarts MJ, Peters FP, Mandigers CM et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. doi:10.1200/JCO.2012.44.6229

17.

Chen-Hardee S, Chrischilles EA, Voelker MD et al (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control 17:647–654. doi:10.1007/s10552-005-0502-4 PubMedCrossRef

18.

National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guideline in oncology myeloid growth factors. http://www.nccn.org. Accessed Dec 2013

19.

Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427–437. doi:10.1634/theoncologist.10-6-427 PubMedCrossRef

20.

Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32PubMedCrossRef

21.

Choi MR, Solid CA, Chia VM et al (2014) Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer 22:1619–1628. doi:10.1007/s00520-014-2121-7 PubMedCrossRef

22.

Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed

23.

Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266. doi:10.1002/cncr.21847 PubMedCrossRef

24.

Mayordomo JI, López A, Viñolas N et al (2009) Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 25:2533–2542. doi:10.1185/03007990903209563 PubMedCrossRef

25.

Wingard JR, Elmongy M (2009) Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72:144–154. doi:10.1016/j.critrevonc.2009.01.003 PubMedCrossRef

26.

Yoshida M, Ohno R (2004) Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 39(Suppl 1):S65–S67. doi:10.1086/383058 PubMedCrossRef

27.

National Collaborating Centre for Cancer. NICE Clinical Guideline Evidence review (2012) Prevention and management of neutropenic sepsis in cancer patients. http://www.nice.org.uk/nicemedia/live/13905/61101/61101.pdf. Accessed Dec 2013

28.

Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354:2034–2045. doi:10.1056/NEJMra052706 PubMedCrossRef

29.

Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205. doi:10.1200/JCO.2006.06.4451 PubMedCrossRef

30.

Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248–v251. doi:10.1093/annonc/mdq195 PubMedCrossRef

31.

Chirivella I, Bermejo B, Insa A et al (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479–484. doi:10.1007/s10549-008-0018-1 PubMedCrossRef

32.

Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283. doi:10.1007/s00277-007-0399-y PubMedCrossRef

33.

Jakobsen A, Berglund A, Glimelius B et al (2002) Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 41:525–531PubMedCrossRef

34.

Radosavljevic D, Golubicic I, Gavrilovic D, et al. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? J BUON 14:203–209

35.

Neupogen (filgrastim). Thousand Oaks, CA: Amgen, (package insert) (2012). http://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf. Accessed July 2013

36.

Neulasta (pegfilgrastim). Thousand Oaks, CA: Amgen, (package insert) (2011). https://www.amgen.ca/Neulasta_PM.pdf. Accessed July 2013

37.

European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) (2006) Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002958c&jsenabled=true. Accessed Oct 2013

38.

Gabrilove JL, Jakubowski A, Fain K et al (1988) Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82:1454–1461. doi:10.1172/JCI113751 PubMedCentralPubMedCrossRef

39.

Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324PubMedCrossRef

40.

Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170. doi:10.1056/NEJM199107183250305 PubMedCrossRef

41.

Yang B-B, Kido A, Shibata A (2007) Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 27:1387–1393. doi:10.1592/phco.27.10.1387 PubMedCrossRef

42.

Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35PubMedCrossRef

43.

Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731PubMedCrossRef

44.

Von Minckwitz G, Kümmel S, du Bois A et al (2008) Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19:292–298. doi:10.1093/annonc/mdm438 CrossRef

45.

Weycker D, Malin J, Kim J et al (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069–1081. doi:10.1016/j.clinthera.2009.05.019 PubMedCrossRef

46.

Cooper KL, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. doi:10.1186/1471-2407-11-404 PubMedCentralPubMedCrossRef

47.

Naeim A, Henk HJ, Becker L et al (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:11. doi:10.1186/1471-2407-13-11 PubMedCentralPubMedCrossRef

48.

Weycker D, Hackett J, Edelsberg JS et al (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402–407. doi:10.1345/aph.1G516 PubMedCrossRef

49.

Tjan-Heijnen VC, Biesma B, Festen J et al (1998) Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J Clin Oncol 16:2708–2714PubMed

50.

Burris HA, Belani CP, Kaufman PA et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6:133–140. doi:10.1200/JOP.091094 PubMedCentralPubMedCrossRef

51.

Zwick C, Hartmann F, Zeynalova S et al (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22:1872–1877. doi:10.1093/annonc/mdq674 PubMedCrossRef

52.

Hartmann LC, Tschetter LK, Habermann TM et al (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776–1780. doi:10.1056/NEJM199706193362502 PubMedCrossRef

53.

Clark OAC, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214. doi:10.1200/JCO.2005.05.645 PubMedCrossRef

54.

Bohlius J, Herbst C, Reiser M, et al. (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane database Syst Rev CD003189. doi: 10.1002/14651858.CD003189.pub4

55.

Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167. doi:10.1200/JCO.2006.08.8823 PubMedCrossRef

56.

Lyman GH, Dale DC, Wolff DA et al (2010) Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28:2914–2924. doi:10.1200/JCO.2009.25.8723 PubMedCrossRef

57.

Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475–2484. doi:10.1093/annonc/mdt226 PubMedCentralPubMedCrossRef

58.

Dubois RW, Pinto LA, Bernal M et al (2004) Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Support Cancer Ther 2:34–41. doi:10.3816/SCT.2004.n.020 PubMedCrossRef

59.

Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112–128. doi:10.1016/j.critrevonc.2013.08.006 PubMedCrossRef

60.

Veerappan R, Morrison M, Williams S, Variakojis D (2007) Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant 40:361–364. doi:10.1038/sj.bmt.1705736 PubMedCrossRef

61.

Martin WG, Ristow KM, Habermann TM et al (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23:7614–7620. doi:10.1200/JCO.2005.02.7243 PubMedCrossRef

62.

Saxman SB, Nichols CR, Einhorn LH (1997) Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 111:657–660PubMedCrossRef

63.

Potosky AL, Malin JL, Kim B et al (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103:979–982. doi:10.1093/jnci/djr152 PubMedCentralPubMedCrossRef

64.

Krzemieniecki K, Sevelda P, Erdkamp F et al (2014) Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. Support Care Cancer 22:667–677. doi:10.1007/s00520-013-2021-2 PubMedCentralPubMedCrossRef

65.

Sierra J, Szer J, Kassis J et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8:195. doi:10.1186/1471-2407-8-195 PubMedCentralPubMedCrossRef

66.

Koumakis G, Vassilomanolakis M, Barbounis V et al (1999) Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 56:28–35PubMedCrossRef

67.

Scott SD, Chrischilles EA, Link BK et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm 9:15–21

68.

Lyman GH, Barron RL, Natoli JL, Miller RM (2012) Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol 81:296–308. doi:10.1016/j.critrevonc.2011.04.010 PubMedCrossRef

69.

Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21:1431–1439. doi:10.1200/JCO.2003.09.081 PubMedCrossRef

70.

Bonilla L, Ben-Aharon I, Vidal L et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845–1854. doi:10.1093/jnci/djq409 PubMedCentralPubMedCrossRef

71.

Lee YM, Lockwood C (2013) Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis. Int J Nurs Pract 19:557–576. doi:10.1111/ijn.12099 PubMedCrossRef

72.

Gridelli C, Aapro MS, Barni S et al (2007) Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol 63:53–64. doi:10.1016/j.critrevonc.2007.01.008 PubMedCrossRef

73.

Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917–1927. doi:10.1002/cncr.25691 PubMedCentralPubMedCrossRef

74.

Schnipper LE, Smith TJ, Raghavan D et al (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30:1715–1724. doi:10.1200/JCO.2012.42.8375 PubMedCrossRef

Title: Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia
Authors: Sol Cortés de Miguel
Miguel Ángel Calleja-Hernández
Salomón Menjón-Beltrán
Inmaculada Vallejo-Rodríguez
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2459-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Is there coronary artery disease in the cancer patient who manifests with chest pain, shortness of breath and/or tachycardia? A retrospective observational cohort

Reproductive health and endocrine disruption in women with breast cancer: a pilot study

Validation of the Holistic Comfort Questionnaire- caregiver in Portuguese-Brazil in a cohort of informal caregivers of palliative care cancer patients

The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study

Erratum to: Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

The Spanish version of the Body Image Scale (S-BIS): psychometric properties in a sample of breast and gynaecological cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer